

Reasons to invest

LO Selection – NextGen BioTech

Why invest?

p.4



Equities



p.2-7

· Product overview	2
· Why invest?	4
· Investment philosophy and process	5
· The investment team	5
· Sub-Fund key facts	6
· Understanding risks & glossary	7

Health is our only wealth.

Publication issued by Lombard Odier Asset Management (Europe) Limited (“LOIM”)

Lombard Odier Selection (“LO Selection”) is a variable capital investment company (SICAV) incorporated in Luxembourg as an Undertaking for Collective Investments in Transferable Securities (UCITS) subject to Luxembourg laws. NextGen BioTech is a Sub-Fund of LO Selection.

This marketing document is for retail investors located in the countries listed in the Key Facts section. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000. It is not appropriate for retail investors in Singapore or any US person/It is not appropriate for any US person. Please read the important information at the end of this document.

Product overview

ASSET CLASS

Equities.

APPROACH

High Conviction.

At Lombard Odier Investment Managers, we think that investing is always linked to a view of the future.

NextGen BioTech is about investing in small and mid companies which develop disruptive technologies in the healthcare industry.

Indeed, our strategy and investment philosophy have targeted several technology successes in gene therapeutics, cancer, rare diseases, hybrid artificial pancreas and neurology.

As an illustration, we had identified the mRNA¹ technology in its early days, as we had invested in Moderna; it now proved to help the world fighting against Covid-19.

Lastly, the strategy is about having a positive impact on patients' lives, making healthcare expenses less expensive to our economies, hence a positive impact for the whole society. Because scientific innovation is more than ever to take care of our most valuable asset, our health.


¹ mRNA stands for messenger RNA. It plays a central role in the production of the proteins in the body. The mRNA vaccines contain the construction plan for a specific part of a virus. When a protein covers the surface of a virus it is therefore recognisable by the immune system.

NextGen BioTech: Positive impact for patients through disruptive technologies



Expensive healthcare bills

Healthcare expenses are outpacing economic growth, reaching levels that are both unaffordable and unsustainable.



Innovation

is the only sustainable answer to:

- address unmet medical needs,
- lower the financial burden,
- increase healthcare access.



Small/mid cap healthcare companies offer a sweet spot

We believe that healthcare innovation primarily relies on small-mid cap companies. This has been further validated by the Covid-19 pandemic, with the development in record times of safe and effective vaccines, or the adoption of remote monitoring solutions, helping healthcare practitioners to take care of their patients.

Source: LOIM. For illustrative purposes only.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Why invest?

Innovation in healthcare leads to a virtuous circle.

“NextGen BioTech invests in early-stage disruptive technologies, with the potential to better understand the biology of the conditions, improve diagnostic tools, help new drugs development, ultimately address incurable diseases, and by doing so helping patients and solve societal issues.”

Jerome Berton,
Lead Portfolio Manager

Connected solutions for a more personalised treatment

Digital solutions transform the delivery of care:

- Improved access: Virtual GP visits, improving access to specialists, enhancing prescriptions fulfillment and delivery.
- Improved quality: Monitoring devices continuously capture data for actionable therapeutic insights, digital platforms offer personalized recommendations.
- Improved efficiency: Lowering medical errors and reducing costs.

A sweet spot in healthcare

Small and Mid cap companies in healthcare offer a sweet spot for investing and we believe therapeutic innovation primarily relies on those companies, as shown by Covid-19 that has acted as an enabler, validating some emerging technologies (such as the mRNA platform).

We believe in the performance potential in many NextGen BioTech stocks as:

- Scientific innovation is the cornerstone for value creation.
- Companies could have outsized growth potential.
- An expanding portfolio of technologies can enable to capture value.
- Small and Mid cap market is an attractive pool of Merger & Acquisition targets.


Three themes for disruptive innovation

I-Cure diseases with novel therapeutics



- Novel therapeutics come with the promise to cure diseases.
- Access to more effective treatments with an improved benefit/risk ratio.

II-Screening solutions across the whole disease cycle



- Critical role to support treatment decisions; expected to be granted more value in the future.
- New methods for early diagnostics bring efficiency: better health outcomes, reduced global costs.

III-Big Data for better patient care



- Digital embedded solutions transform the delivery of care, and offer improved access, quality and efficiency.
- Digitalisation provides insightful data for personalised treatments.


¹ Source: For illustrative purposes only. There can be no assurance that the investment objective will be achieved or that there will be a return on capital or that a substantial loss will not be incurred.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Investment philosophy and process

At Lombard Odier Investment Managers, we believe disruptive healthcare technologies will drive positive impact for patients' life

From a universe of opportunities to a high conviction portfolio



Source: LOIM. ¹ Key focus sectors: healthcare, IT, communication services and industrials. Minimum USD 1 million average daily liquidity. Allocations are subject to change. It illustrates the investment process undertaken by the manager in respect of a certain type of investment but may not be representative of the Fund's past or future portfolio of investments. For illustrative purposes only.

The investment team



Jerome Berton
Lead Portfolio Manager



Henk Grootveld
Backup Portfolio Manager



Didier Rabattu
Head of Equities



Pascal Menges
Head of Research

Source: LOIM as at 1 January 2022. The investment management team is subject to change without notice.¹ The number of years denotes years of investment industry experience.

For illustrative purposes only. Holdings/allocation are subject to change. Past performance and forecasts are not a reliable indicator of future returns of the Sub-Fund. For more information on the LOIM ESG process please refer to the following link: <https://am.lombardodier.com/home/the-sustainability-revolution-wi.html/>. There can be no assurance that the Sub-Fund's investment objective will be achieved or that there will be a return on capital or that a substantial loss will not be incurred.

This marketing document is for retail investors located in the countries listed on Section - Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Key facts about LO Selection – NextGen BioTech

Legal structure	SICAV – UCITS (Luxembourg) ¹
Investment objectives	The Sub-Fund invests primarily in equity securities or equity-related securities issued by companies worldwide (including Emerging Markets) exercising a prominent part of their business activities in the healthcare industry. The Investment Manager’s approach focuses on small healthcare companies providing innovative technologies that have the potential to reshape the healthcare industry. The Sub-fund is actively managed in reference to a benchmark. The NASDAQ Biotechnology Net TR Index (the “Benchmark”) is used for performance comparison and for internal risk monitoring purposes only, without implying any particular constraints to the Sub-Fund’s investments. The Sub-Fund’s securities will generally be members of the Benchmark but the security weightings are expected to differ materially. The Investment Manager will select securities not included in the Benchmark in order to take advantage of investment opportunities. The Investment Manager will use its discretion with regard to the selection of markets, size of companies and currencies. The Sub-Fund may (i) hold on a temporary and ancillary basis up to 30% of its net assets in Cash and Cash Equivalents and (ii) hold up to 10% of its net assets in UCIs. Subject to the limits permitted by the Investment Restrictions described in Section 4 of the Prospectus, the Investment Manager is authorized to use financial derivative instruments for hedging and efficient portfolio management purposes. As part of its Emerging Market exposure, the Sub-Fund may invest up to 20% of its net assets in shares issued by mainland China in-corporated companies (including China A-Shares).
Investor profile	This Sub-Fund may not be appropriate for investors who plan to withdraw their money within 5 years.
Sub-Fund launch	14 January 2021
Custodian bank/administration	CACEIS Bank, Luxembourg Branch
Liquidity	Daily
Subscription/redemption details	12 pm CET; Payment date: T+2
Registered countries/Investor type	Registered for distribution to retail investors in: Austria (AT), Finland (FI), France (FR), Germany (DE), Italy (IT), Liechtenstein (LI), Luxembourg (LU), Netherlands (NL), Norway (NO), Spain (ES), Sweden (SE), United Kingdom (GB). Switzerland (CH): Registered for distribution to Swiss retail investors with the FINMA. Belgium (BE): Not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000. US: Not appropriate for U.S. persons.
Reference currency	USD
Minimum investment	USD 3,000 or equivalent
Management fee	1.20%
Distribution fee	0.75%
Conversion fee	Up to 0.50% (of the total amount switched)
Taxation in the EU	Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Please consult your tax advisor for more details.

Share class	ISIN	SRRI	Entry charge	Ongoing charge ²	Exit charge	Performance fee	Countries of registration
(USD) P Accumulated	LU2265257852	7	Up to 5.00%	2.21%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG
(USD) P Distributed	LU2265257936	7	Up to 5.00%	2.20%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG
Syst. Hdg, (CHF) P Accumulated	LU2265259478	7	Up to 5.00%	2.22%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG
Syst. Hdg, (CHF) P Distributed	LU2265259551	7	Up to 5.00%	2.19%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG
Syst. Hdg, (EUR) P Accumulated	LU2265260724	7	Up to 5.00%	2.22%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG
Syst. Hdg, (EUR) P Distributed	LU2265260997	7	Up to 5.00%	2.21%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG
Syst. Hdg, (GBP) P Accumulated	LU2265262266	7	Up to 5.00%	2.21%	0.00%	None	BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SG

The above share classes are for illustrative purposes only. Other share classes may be available in your country. The prospectus, the Key Investor Information Documents (KIIDs), the articles of incorporation as well as the semi-annual and annual reports are available on www.loim.com and can be requested free of charge at the registered office of the Sub-Fund. When all or part of the costs are in another currency than yours, the costs may increase as a result of currency and exchange rate fluctuations.

¹ Lombard Odier Selection (“LO Selection”) is a variable capital investment company (SICAV) incorporated in Luxembourg as an Undertaking for Collective Investments in Transferable Securities (UCITS) subject to Luxembourg laws. NextGen BioTech is a Sub-Fund of LO Selection. / ² The ongoing charges figure is based on expenses for the 12-month period ending 31 December 2022. This figure may vary periodically. / ³ The Sub-Fund is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Contact

To find out more about LO Selection – NextGen BioTech, email loim-funds@lombardodier.com

or visit www.loim.com  [@loimnews](https://twitter.com/loimnews) 

IMPORTANT INFORMATION

Lombard Odier Selection (hereinafter the “Fund”) is a Luxembourg investment company with variable capital (SICAV). The Fund is authorised and regulated by the Luxembourg Supervisory Authority of the Financial Sector (CSSF) as an Undertaking for Collective Investments in Transferable Securities UCITS under Part I of the Luxembourg law of the 17 December 2010 implementing the European directive 2009/65/EC, as amended (“UCITS Directive”). This marketing document particularly relates to **NextGen BioTech**, a Sub-Fund of LO Selection (hereinafter the “Sub-Fund”).

The Management Company of the Fund is Lombard Odier Funds (Europe) S.A. (hereinafter the “Management Company”), a Luxembourg based public limited company (SA), having its registered office at 291, route d’Arlon, 1150 Luxembourg, authorised and regulated by the CSSF as a Management Company within the meaning of EU Directive 2009/65/EC, as amended; and within the meaning of the EU Directive 2011/61/EU on Alternative Investment Fund Managers (AIFMD). The purpose of the Management Company is the creation, promotion, administration, management and the marketing of Luxembourg and foreign UCITS, alternative investment funds (“AIFs”) and other regulated funds, collective investment vehicles or other investment vehicles, as well as the offering of portfolio management and investment advisory services.

The information contained herein is subject to completion and amendment. This marketing communication was prepared and issued by Lombard Odier Asset Management (Europe) Limited. Lombard Odier Investment Managers (“LOIM”) is a trade name.

The prospectus, the articles of incorporation, the Key Investor Information Documents, the subscription form and the most recent annual and semi-annual reports are the only official offering documents of the Sub-Fund’s shares (the “Offering Documents”). The Offering Documents are/will become available in English, French, German and Italian at www.loim.com and can be requested free of charge at the registered office of the Sub-Fund in Luxembourg: 291 route d’Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg.

The information contained in this marketing communication does not take into account any individual’s specific circumstances, objectives or needs and does not constitute research or that any investment strategy is suitable or appropriate to individual circumstances or that any investment or strategy constitutes a personal investment advice to any investor. This marketing communication is not intended to substitute any professional advice on investment in financial products. Before making an investment in the Sub-Fund, an investor should read the entire Offering Documents, and in particular the risk factors, costs and conditions pertaining to an investment in the Sub-Fund. We would like to draw the investor’s attention toward the long-term nature of delivering returns across the economic cycle and the use of financial derivative instruments as part of the investment strategy may result in a higher level of leverage and increase the overall risk exposure of the Sub-Fund and the volatility of its Net Asset Value. Investors should take care to assess the suitability of such investment to his/her particular risk profile and circumstances and, where necessary, obtain independent professional advice in respect of risks, as well as any legal, regulatory, credit, tax, and accounting consequences. There can be no assurance that the Sub-Fund’s investment objective will be achieved or that there will be a return on capital. Past performance is not a reliable indicator of future results. Where the Sub-Fund is denominated in a currency other than an investor’s base currency, changes in the rate of exchange may have an adverse effect on price and income. Please take note of the risk factors.

The management company of the sub-fund / Fund may decide at any time to cease marketing in your country.

For a summary of your investor rights and guidelines related to an individual or collective action for litigation on a financial product at EU level and in your country of residence, please refer to the following link: <https://am.lombardodier.com/home/asset-management-regulatory-disc.html>

The summary is available in English or in one authorised language in your country. MSCI information may only be used for internal purposes, may not be reproduced or disseminated in any form whatsoever and may not be used as the basis or constituent element of any financial instruments, products or indices.

MSCI information should not be construed as investment advice or recommendations to you to make (or refrain from making) any investment decision and cannot, as such, be considered reliable. Historical data and analyses should not be considered as any indication or guarantee in any analysis, forecast or prediction of future performance. MSCI information is provided “as is” and the user of this information assumes full responsibility for the use that is made of this information. MSCI, each of its affiliates and others involved in or concerned with the compilation, calculation or creation of MSCI information (collectively the “MSCI Parties”) expressly disclaim all warranties (including, without limitation, all warranties of originality, accuracy, completeness, timeliness, non-infringement, market value and fitness for a specific purpose) with respect to such information. Without limiting the foregoing, in no event shall the MSCI Parties be liable for any direct, indirect, specific, incidental, punitive, consequential (including, without limitation, lost profits) or other damages. (www.msci.com).

Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of a Sub-Fund. The performance of a benchmark shall not be indicative of past or future performance of any Sub-Fund. It should not be assumed that the relevant Sub-Fund will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between such Sub-Fund’s returns and any index returns. Target performance/risk represents a portfolio construction goal. It does not represent past performance/risk and may not be representative of actual future performance/risk.

The information and analysis contained herein are based on sources considered to be reliable. Lombard Odier makes its best efforts to ensure the timeliness, accuracy, and completeness of the information contained in this marketing communication.

Nevertheless, all information and opinions as well as the prices, market valuations and calculations indicated herein may change without notice. Source of the figures: Unless otherwise stated, figures are prepared by Lombard Odier Asset Management (Europe) Limited. The tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Lombard Odier does not provide tax advice and it is up to each investor to consult with its own tax advisors.

Austria: Paying agent: Erste Bank der österreichischen Sparkassen AG
Belgium: Financial Services Provider: CACEIS Belgium S.A. The Sub-Fund is not appropriate for Belgian retail investors unless the investment subscription is more than EUR250,000. Please contact your financial adviser to identify the impacts of the Belgian tax “TOB” (“Taxe sur les Opérations Boursières”) on your transactions as well as the impacts of the withholding tax (“Précomptes mobiliers”). Lombard Odier has an internal Complaints Management Service. You can lodge a claim via your Relationship Manager or directly to Lombard Odier (Europe) S.A. Luxembourg, Belgium Branch, Claim Management Service, Avenue Louise 81, Box 12, 1050 Brussels, Fax: (+32) 254308. Alternatively, you can address your complaint free of charge to the national complaint service in Belgium, OMBUDSMAN: North Gate II, Boulevard du Roi Albert II, no 8, Boite 2 2, 1000 Brussels, Tel: (+32) 2 545 77 70, Fax: (+32) 2 545 77 79, Email: Ombudsman@Ombudsfm.be.

Germany: German Information and Paying agent: Deka Bank Deutsche Girozentrale
Italy: Paying agents: Société Générale Securities Services S.p.A., State Street Bank International GmbH - Succursale Italia, Banca Sella Holding S.p.A., Allfunds Bank S.A., Italian Branch, BNP Paribas Securities Services, CACEIS Bank Italy Branch Liechtenstein: Paying agent – LGT Bank AG.

Luxembourg: Custodian, central administration agent, registrar, transfer Agent, paying agent and listing agent: CACEIS Bank, Luxembourg Branch

Netherlands: Paying agent: Lombard Odier Funds (Europe) S.A. Dutch branch
Singapore: This marketing communication has been approved for use by Lombard Odier (Singapore) Ltd for the general information of accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the Securities and Futures Act (Chapter 289). Recipients in Singapore should contact Lombard Odier (Singapore) Ltd, an exempt financial adviser under the Financial Advisers Act (Chapter 110) and a merchant bank regulated and supervised by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with this marketing communication. The recipients of this marketing communication represent and warrant that they are accredited investors and other persons as defined in the Securities and Futures Act (Chapter 289). This advertisement has not been reviewed by the Monetary Authority of Singapore. Spain: Paying agent: Allfunds Bank, S.A. – CNMV number: 498

Sweden: Paying agent: Skandinaviska Enskilda Banken AB (publ)
Switzerland: The Sub-Fund is registered with the Swiss Federal Financial Market Supervisory Authority (FINMA). The Offering Documents together with the other Shareholders’ information are/will become available free of charge at the Swiss Representative: Lombard Odier Asset Management (Switzerland) SA., 6, avenue des Morgines, 1213 Petit-Lancy, Switzerland. Swiss Paying Agent: Banque Lombard Odier & Cie SA, 11, rue de la Corrairie 1204 Genève, Switzerland. Publications about the Sub-Fund: www.fundinfo.com. The issue and redemption prices and/or the net asset value (with the mention “excluding commissions”) of the Share classes distributed in Switzerland: www.swissfunddata.ch and www.fundinfo.com. Bank Lombard Odier & Co Ltd is a bank and securities dealer authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA)

United Kingdom: This document is a financial promotion and has been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000, by Lombard Odier Asset Management (Europe) Limited. It is approved for distribution by Lombard Odier (Europe) SA, London Branch for Retail Clients in the United Kingdom. The Sub-Fund is a Recognised scheme in the United Kingdom under the Financial Services and Markets Act 2000. UK regulation for the protection of retail clients in the UK and the compensation available under the UK Financial Services Compensation scheme does not apply in respect of any investment or services provided by an overseas person. UK facilities agent: Lombard Odier Asset Management (Europe) Limited. Lombard Odier (Europe) S.A. UK Branch, a credit institution regulated in the UK by the Prudential Regulation Authority (PRA) and subject to limited regulation by the Financial Conduct Authority (‘FCA’) and the Prudential Regulation Authority (‘PRA’). Details of the extent of our authorisation and regulation by the PRA and regulation by the FCA are available from us on request. European Union Members: This marketing communication has been approved for use by Lombard Odier (Europe) S.A. The entity is a credit institution authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg. Lombard Odier (Europe) S.A. branches are operating in the following territories: Belgium. Supervisory Authority: Autorité des services et marchés financiers (FSMA), Representative: CACEIS Belgium S.A., Avenue du Port 86C, b320, 1000 Brussels - France: Lombard Odier (Europe) S.A. Succursale en France, a credit institution under limited supervision in France by the Autorité de contrôle prudentiel et de résolution (ACPR) and by the Autorité des marchés financiers (AMF) in respect of its investment services activities; Italy: Lombard Odier (Europe) S.A. Succursale in Italia, enrolled in the Milan Companies Register No. 09514880963, R.E.A. No. MI – 2095300. Regulated in Italy by the Commissione Nazionale per la Società e la Borsa (CONSOB) and la Banca d’Italia; Spain: Lombard Odier (Europe) S.A. Sucursal en España, Lombard Odier Gestión (España) S.G.I.I.C., S.A.U., credit institutions under limited supervision in Spain by the Banco de España and the Comisión Nacional del Mercado de Valores (CNMV). United States: Neither this document nor any copy thereof may be sent, taken into, or distributed in the United States or given to any US person.

This marketing communication may not be reproduced (in whole or in part), transmitted, modified, or used for any public or commercial purpose without the prior written permission of Lombard Odier.

©2022 Lombard Odier IM. All rights reserved